NIH Launches Clinical Trial for Universal Flu Vaccine Using mRNA Technology
by
kamal ji
Promising Universal Flu Vaccine Enters Early-Stage Trial by National Institutes of Health
The National Institutes of Health (NIH) is conducting an early-stage clinical trial for a universal flu vaccine
based on mRNA technology. The vaccine aims to protect against various flu strains and provide long-term
immunity, eliminating the need for annual shots.
The mRNA platform, used in Moderna's and Pfizer's COVID vaccines, was developed with NIH's involvement. The trial will enroll up to 50 healthy participants to assess safety and immune response.
Researchers at the NIH's National Institute of Allergy and Infectious Diseases developed the universal flu vaccine, and the trial is taking place at Duke University.
Current flu vaccines' effectiveness varies yearly, and a universal vaccine could be a crucial defense against future flu pandemics.